Respiratory Inhalers Market, By Type (Manually Operated and Digitally Operated), By Product (Dry Powder Inhaler, Metered Dose Inhaler, Others), By Application (Asthma, Chronic Obstructive Pulmonary Disease (COPD), Arterial Hypertension, Other), By End User (Hospitals & Clinics, Respiratory Care Center, Academic and Research Institutes, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Feb 2025

Code : CMI227

Pages :180

Formats :

Excel and PDF

Industry : Medical Devices

Respiratory Inhalers Market Size and Trends

Global respiratory inhalers market is estimated to be valued at USD 35.10 Bn in 2025 and is expected to reach USD 52.81 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 6.0% from 2025 to 2032.

Respiratory Inhalers Market Key Factors

To learn more about this report, Request sample copy

Rising prevalence of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) can boost demand for respiratory inhalers. Asthma currently affects over 300 million people worldwide and is one of the most common chronic diseases among children. Incorrect usage of inhalers and lack of disease awareness regarding proper utilization of inhalers in developing nations can hamper the market growth. However, ongoing research & development activities for development of more effective and affordable respiratory inhalers can offer growth opportunities for the market players.

Increasing Prevalence of Respiratory Diseases

Rising prevalence of respiratory diseases such as asthma and COPD across the world can boost demand for respiratory inhalers. Chronic respiratory conditions tend to worsen with age, and with an increasingly aging global population, the problem is further exacerbated. Data from health organizations shows a steady growth in the number of people diagnosed with asthma and COPD each year. This upward trend is seen prominently in developed as well as developing nations. For instance, as per some studies, around 235 million people are estimated to be suffering from asthma currently worldwide. This number can reach 400 million by 2025. Exposure to indoor and outdoor pollution, occupational hazards, and smoking are the primary causes of respiratory illnesses. As patient pool expands consistently, respiratory inhalers are used as the preferred mode of drug delivery in asthma and COPD management. Inhaled medications allow for direct targeting of the airways, ensuring better therapeutic response with minimal systemic side effects. This also permits use of higher dose with greater safety. The ongoing development and approval of newer and more effective inhaled drugs can boost inhaler consumption. with progressive morbidity and mortality associated with respiratory infections, inhaler therapy adoption is likely to maintain its northward trajectory in the coming years from both healthcare as well as patient perspectives. Unrelenting urbanization and pollution levels across large sections of the globe can cause asthma and COPD.